Brújula Home

Institutional repository of the Universidad Loyola

View Item 
  •   Brújula Home
  • PRODUCCIÓN CIENTÍFICA Y TRANSFERENCIA
  • Departamento de Salud
  • Artículos
  • View Item
  •   Brújula Home
  • PRODUCCIÓN CIENTÍFICA Y TRANSFERENCIA
  • Departamento de Salud
  • Artículos
  • View Item
    • español
    • English
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browse

All of BrújulaCommunities and CollectionsAuthorsTitlesKeywordsAuthor profilesThis CollectionAuthorsTitlesKeywords

My Account

Login

Statistics

View Usage Statistics

Añadido Recientemente

Novedades
Repository
How to publish
Visibility
FAQs

Antiadenovirus drug discovery: potential targets and evaluation methodologies.

Author:
Sánchez-Céspedes, Javier; Serna-Gallego, Ana; Martínez Aguado, Pablo; Marrugal-Lorenzo, Jose Antonio; Gómez-Marín, Isabel
URI:
https://hdl.handle.net/20.500.12412/7055
ISSN:
1359-6446
DOI:
10.1016/j.drudis.2015.07.007
Date:
2015-10-01
Abstract:

Human adenoviruses (HAdV) are the cause of many acute infections, mostly in the respiratory and gastrointestinal (GI) tracts, as well as conjunctivitis. HAdV diseases in immunocompetent individuals are mostly self-limiting; however, in immunocompromised individuals, especially in pediatric units, HAdV infections are the cause of high morbidity and mortality. Despite the significant clinical impact, there are currently no approved antiviral therapies for HAdV infections. Here, we provide an overview of the different targets that could be considered for the design of specific drugs against HAdV, as well as the available in vitro and in vivo tools for the screening and evaluation of candidate molecules.

Human adenoviruses (HAdV) are the cause of many acute infections, mostly in the respiratory and gastrointestinal (GI) tracts, as well as conjunctivitis. HAdV diseases in immunocompetent individuals are mostly self-limiting; however, in immunocompromised individuals, especially in pediatric units, HAdV infections are the cause of high morbidity and mortality. Despite the significant clinical impact, there are currently no approved antiviral therapies for HAdV infections. Here, we provide an overview of the different targets that could be considered for the design of specific drugs against HAdV, as well as the available in vitro and in vivo tools for the screening and evaluation of candidate molecules.

Show full item record
Collections
  • Artículos
Files in this item
Thumbnail
DrugDiscoveryToday_AAM_prepared.docx (357.9Kb)
Share
Export to Mendeley
Statistics
Usage statistics
Metrics and citations  
Go to Brújula home

Universidad Loyola

Library

Contact

Facebook Loyola BibliotecaTwitter Loyola Biblioteca

The content of the Repository is protected with a Creative Commons license:

Attribution-NonCommercial-NoDerivatives 4.0 Internacional

Creative Commons Image